Iberdomide (CC220) - 97%, high purity , CAS No.1323403-33-3, cereblon

Item Number
I414161
Grouped product items
SKUSizeAvailabilityPrice Qty
I414161-2mg
2mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$68.90
I414161-5mg
5mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$117.90
I414161-10mg
10mg
In stock
$206.90
I414161-25mg
25mg
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$414.90
I414161-50mg
50mg
In stock
$741.90
I414161-100mg
100mg
In stock
$1,175.90

E3 ligase Ligand

Basic Description

SynonymsDB12101 | 1323403-33-3 | A903376 | AKOS032946272 | CC 220;CC-220;Iberdomide | SR-01000426667-1 | HY-101291 | Iberdomide [USAN] | 8W7 | EX-A1425 | IBERDOMIDE [WHO-DD] | (S)-3-(4-((4-(Morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione |
Specifications & PurityMoligand™, ≥97%
Biochemical and Physiological MechanismsIberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon, part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunosti
Storage TempProtected from light,Store at -20°C
Shipped InIce chest + Ice pads
GradeMoligand™
Mechanism of actioncereblon
Product Description

Information

Iberdomide (CC-220) is a novel oral immunomodulatory compound that targets cereblon , part of the CRL4CRBN E3 ubiquitin ligase complex, with an IC50 of 60 nM in a competitive TR-FRET assay. Iberdomide (CC-220) induces apoptosis with antitumor and immunostimulatory activities.


Targets

cereblon 60 nM


In vitro

In cellular degradation assays, treatment with CC-220 results in the loss of Ikaros protein levels with an EC50 of 1 nM compared to 67 nM for lenalidomide and 24 nM for pomalidomide. CC-220 is similarly potent toward Aiolos, with an EC50 of 0.5 nM compared to 87 nM for lenalidomide and 22 nM for pomalidomide. CC-220 is a potent anti-proliferative and pro-apoptotic compound that shows activity in several MM cell line categories with differing sensitivity to lenalidomide, pomalidomide and dexamethasone. CC-220 induces PBMC-mediated killing of all MM cell lines regardless of the level of Cereblon expression and cell autonomous sensitivity. CC-220 acts through binding of Cereblon, leading to the degradation of the hematopoietic transcription factors Ikaros and Aiolos, followed by disruption of the MM promoting c-Myc/IRF4 axis.

Product Properties

ALogP1.56
HBD Count1
Rotatable Bond6

Associated Targets(Human)

CRBN Tclin Protein cereblon (1 Activities)
Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)
RPMI-8226 (44974 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MV4-11 (7307 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CRBN Tclin Protein cereblon (139 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CSNK1A1 Tchem Cereblon/Casein kinase I alpha (35 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CRBN Tclin Cereblon/Ikaros (139 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CRBN Tclin Cereblon/Aiolos (164 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CRBN Tclin Cereblon/GSPT1 (159 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
MM1.S (1111 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

rep Replicase polyprotein 1ab (378 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Names and Identifiers

IUPAC Name (3S)-3-[7-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione
INCHI InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1
InChi Key IXZOHGPZAQLIBH-NRFANRHFSA-N
Canonical SMILES C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5
Isomeric SMILES C1CC(=O)NC(=O)[C@H]1N2CC3=C(C2=O)C=CC=C3OCC4=CC=C(C=C4)CN5CCOCC5
Alternate CAS 1323403-33-3
PubChem CID 67335295
MeSH Entry Terms (3S)-3-(4-((4-((morpholin-4-yl)methyl)phenyl)methoxy)-1-oxo-1,3-dihydro-2H-isoindol-2-yl)piperidine-2,6-dione;CC-220;CC-220 hydrochloride;CC220;iberdomide;iberdomide hydrochloride
Molecular Weight 449.5

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot NumberCertificate TypeDateItem
G2227946Certificate of AnalysisJun 12, 2022 I414161
G2227947Certificate of AnalysisJun 12, 2022 I414161
G2227948Certificate of AnalysisJun 12, 2022 I414161

Chemical and Physical Properties

SolubilitySolubility (25°C) In vitro DMSO: 90 mg/mL (200.22 mM); Ethanol: 4 mg/mL (8.89 mM); Water: Insoluble;
SensitivityLight sensitive
DMSO(mg / mL) Max Solubility90
DMSO(mM) Max Solubility200.222469410456
Water(mg / mL) Max Solubility<1

Related Documents

References

1. Cai X, Qiao Y, Diao C, Xu X, Chen Y, Du S, Liu X, Liu N, Yu S, Chen D et al..  (2014)  Association between polymorphisms of the IKZF3 gene and systemic lupus erythematosus in a Chinese Han population..  PLoS ONE,  (10): (e108661).  [PMID:25271777] [10.1021/op500134e]
2. Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, Wang M, Ren Y, Couto S, Breider M et al..  (2015)  Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4..  Blood Cancer J,  (13): (e354).  [PMID:26430725] [10.1021/op500134e]
3. Matyskiela ME, Zhang W, Man HW, Muller G, Khambatta G, Baculi F, Hickman M, LeBrun L, Pagarigan B, Carmel G et al..  (2018)  A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos..  J Med Chem,  61  (2): (535-542).  [PMID:28425720] [10.1021/op500134e]

Solution Calculators